HC Wainwright & Co. Maintains Buy on Enlivex Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Enlivex Therapeutics (NASDAQ:ENLV) but has lowered the price target from $7 to $6.
June 11, 2024 | 10:13 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Enlivex Therapeutics but has lowered the price target from $7 to $6.
The maintained Buy rating suggests continued confidence in the stock, but the lowered price target indicates a more cautious outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100